Focal Therapy for Prostate Cancer: Evolutionary Parallels to Breast Cancer Treatment.

breast neoplasms; cryosurgery; photodynamic therapy mastectomy, segmental prostatic neoplasms

Journal

The Journal of urology
ISSN: 1527-3792
Titre abrégé: J Urol
Pays: United States
ID NLM: 0376374

Informations de publication

Date de publication:
01 2023
Historique:
pubmed: 22 9 2022
medline: 15 12 2022
entrez: 21 9 2022
Statut: ppublish

Résumé

Our goal was to review the history of the adoption of focal therapy for breast and prostate cancer and review common barriers to implementation. A narrative review of the literature was performed of English-language MEDLINE indexed articles of breast-conservation therapy and prostate cancer focal therapy. The introduction of focal therapy in breast cancer began with pioneering case series, and multiple randomized trials were performed prior to widespread adoption. Focal therapy for prostate cancer has just started the process of clinical trials with a single published randomized controlled trial. Commonly cited barriers to the adoption of prostate focal therapy include historical views of Halstedian tumor biology, tumor multifocality, over-detection, limitations in prostate imaging, and trial design end points. The adoption of breast-conserving therapy evolved over decades and used data from multiple large, randomized, clinical trials. Barriers to the adoption of prostate cancer local therapy are similar to those faced by breast cancer clinical trials. Completion of well-designed trials in prostate cancer focal therapy is essential for its evidence-based adoption.

Identifiants

pubmed: 36129376
doi: 10.1097/JU.0000000000002972
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

49-57

Commentaires et corrections

Type : CommentIn

Auteurs

Craig V Labbate (CV)

Section of Urology, University of Chicago Medicine, Chicago, Illinois.

Laurence Klotz (L)

Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada.

Monica Morrow (M)

Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.

Matthew Cooperberg (M)

University of California San Francisco, San Francisco, California.

Laura Esserman (L)

University of California San Francisco, San Francisco, California.

Scott E Eggener (SE)

Section of Urology, University of Chicago Medicine, Chicago, Illinois.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH